Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before April 7, 2026 to Discuss Your Rights - INO

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is currently facing legal action for alleged securities law violations, prompting The Gross Law Firm to notify affected investors. Shareholders who purchased INO shares between October 10, 2023, and December 26, 2025, are encouraged to reach out to the firm, especially if they are considering a lead plaintiff role in the class-action suit. Importantly, potential plaintiffs are not required to take on this role to participate in any recovery. Interested shareholders must contact the firm by April 7, 2026.

The lawsuit accuses Inovio's management of issuing misleading statements and failing to disclose critical information regarding its operational integrity, particularly concerning the CELLECTRA device. Key allegations include deficiencies in the device's manufacturing process, which impede the company’s ability to submit its lead product candidate, INO-3107, for FDA approval by the anticipated deadline. Furthermore, the lawsuit claims that Inovio lacked the necessary information to justify the eligibility of INO-3107 for accelerated approval or priority review, leading to an inflated perception of the candidate's regulatory and commercial potential.

Investors who register will be integrated into a monitoring system that offers updates throughout the case. The Gross Law Firm highlights its commitment to protecting investors and holding companies accountable for any deceit or fraud that leads to inflated stock prices. Interested parties can find more details and register online through the firm's dedicated portal.

As this case unfolds, investors are urged to act swiftly to secure their rights and potential recovery by the specified deadline.

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) faces a significant challenge as it has been sued for securities law violations, creating a complex situation for current and potential investors. The class period outlined by The Gross Law Firm, spanning from October 10, 2023, to December 26, 2025, indicates that shareholders may have legal grounds to recover losses related to alleged misleading statements by the company regarding its manufacturing practices and product candidate INO-3107.

For investors, this development raises several important considerations. The allegations suggest that Inovio may have overstated its operational capacity and the prospects of its lead product candidate, which is now unlikely to achieve regulatory approval in the anticipated timeframe. This could lead to a decline in investor confidence and potential volatility in the stock price, making it a hazardous environment for long-term investors.

Investors who purchased shares during the specified class period should consider engaging with legal counsel to understand their options, particularly in light of the upcoming deadline of April 7, 2026, to seek lead plaintiff status. Participating in the class action is a no-obligation opportunity for shareholders to explore recovery avenues without upfront costs, potentially mitigating some of their financial losses.

From a market perspective, potential investors should approach Inovio with caution. The current legal situation could impact the company’s stock performance, overall market sentiment, and long-term growth trajectory. Careful evaluation of the company's financial health, along with developments in the lawsuit, will be critical in making informed investment decisions. Investors should stay updated and prioritize risk management strategies in light of these unfolding events.